Recap: Cocrystal Pharma Q3 Earnings
Portfolio Pulse from Benzinga Insights
Cocrystal Pharma (NASDAQ:COCP) reported Q3 earnings with an EPS of $-0.41, beating estimates by 22.64% but with no change in revenue from the same period last year. The previous quarter's EPS beat was followed by a 1.99% drop in share price the next day.
November 13, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cocrystal Pharma reported a better-than-expected Q3 EPS, beating estimates by 22.64%, but showed no revenue growth from the same period last year.
While Cocrystal Pharma's EPS beat may be viewed positively, the lack of revenue growth could temper investor enthusiasm. Historical data shows a previous EPS beat was followed by a slight drop in share price, suggesting a mixed or neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100